-0.93% were down 1.2% in trading on Monday after the drugmaker said it plans to start Phase 1 clinical trials for an inhaled version of remdesivir, its treatment for severely ill COVID-19 patients."That could have significant implications in helping to stem the tide of the pandemic," CEO Daniel O'Day said in a letter on Monday.